Crossmark Global Holdings Inc. Acquires 4,942 Shares of DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. increased its holdings in shares of DaVita Inc. (NYSE:DVA) by 19.1% during the fourth quarter, HoldingsChannel reports. The firm owned 30,769 shares of the company’s stock after buying an additional 4,942 shares during the period. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $4,601,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Transcendent Capital Group LLC bought a new position in DaVita during the 3rd quarter valued at about $25,000. Blue Trust Inc. lifted its position in DaVita by 56.4% during the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after purchasing an additional 119 shares during the period. Quarry LP purchased a new stake in DaVita in the third quarter worth approximately $60,000. Point72 Hong Kong Ltd bought a new stake in DaVita in the 2nd quarter worth approximately $68,000. Finally, Versant Capital Management Inc raised its stake in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA opened at $168.50 on Thursday. The firm has a market cap of $13.82 billion, a P/E ratio of 18.18, a PEG ratio of 0.81 and a beta of 0.92. DaVita Inc. has a 1-year low of $103.40 and a 1-year high of $170.80. The company has a 50 day simple moving average of $157.81 and a two-hundred day simple moving average of $153.46. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter in the previous year, the company posted $2.85 EPS. The company’s quarterly revenue was up 4.6% on a year-over-year basis. Equities analysts forecast that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the topic of a number of research reports. Truist Financial raised their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.